908 Devices Inc. (MASS) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
908 Devices Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Revenue Outlook
March 7, 2022 4:05 PM EST2021 revenue increases 57% year over year
BOSTON--(BUSINESS WIRE)-- 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter and full year ended December 31, 2021.
2021 was a pivotal year for 908 Devices. We grew revenue 57% over the prior year and demonstrated operational excellence during our first year as a public company. I am so proud of our teams continuous execution against our stated goals, said Kevin J. Knopp, CEO and Co-founder. As the biopharmaceutical industry... More
